Gilead CAR-T Joins Billion-Dollar Club As Biktarvy Sales Cross $10bn Mark

Veklury Declines As COVID-19 Demand Eases

Yescarta surged ahead of competitors Kymriah and Breyanzi, helping Gilead’s oncology sales exceed $2bn, while the company reported the strongest sales in its HIV-dominated core business since 2015.

Gilead Sciences announced its Q4 and FY 2022 earnings on 2 February • Source: Shutterstock

Gilead Sciences, Inc. posted strong revenue growth for the fourth quarter and full year 2022, reporting rapidly growing sales, especially for its top-selling cancer cell therapy and its HIV products, even as sales of its COVID-19 drug, Veklury (remdesivir), continued to see steep declines that appeared to track an overall weakening for the pandemic category across the industry.

The Foster City, CA-based drug maker announced its earnings for 2022 on 2 February, reporting total sales for the fourth...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.